Ignite Creation Date:
2024-05-05 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00426101
Status:
COMPLETED
Last Update Posted:
2018-07-05
First Post:
2007-01-23
Brief Title:
Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004
Sponsor:
Karolinska University Hospital
Organization:
Karolinska University Hospital
Study Overview
Official Title:
HLH-2004 Treatment Protocol
Status:
COMPLETED
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Without therapy HLH is often fatal and often rapidly fatal The treatment protocol HLH-94 has improved survival markedly as compared to the survival earlier We now aim to improve survival further
Detailed Description:
The most dangerous period after HLH diagnosis is the first 2 months In HLH-2004 we provide additional therapy during this period as compared to in HLH-94
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None